These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 21225236

  • 1. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K, Zhang Z, Bai Z, Ma X, Guo W, Wang Y.
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S, Bigand C, Parmentier C, Hajri A.
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M.
    Anticancer Res; 2008 Jul; 28(4B):2205-12. PubMed ID: 18751396
    [Abstract] [Full Text] [Related]

  • 4. p8 is a new target of gemcitabine in pancreatic cancer cells.
    Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn JC, Vasseur S, Iovanna JL.
    Clin Cancer Res; 2006 Jan 01; 12(1):235-41. PubMed ID: 16397047
    [Abstract] [Full Text] [Related]

  • 5. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
    Saiki Y, Yoshino Y, Fujimura H, Manabe T, Kudo Y, Shimada M, Mano N, Nakano T, Lee Y, Shimizu S, Oba S, Fujiwara S, Shimizu H, Chen N, Nezhad ZK, Jin G, Fukushige S, Sunamura M, Ishida M, Motoi F, Egawa S, Unno M, Horii A.
    Biochem Biophys Res Commun; 2012 Apr 27; 421(1):98-104. PubMed ID: 22490663
    [Abstract] [Full Text] [Related]

  • 6. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
    Gao CC, Xu XL, Li F, Gong BG, Liu S, Cui YQ, Sun HC, Xu PY, Zheng YM, Jiang H.
    Tumour Biol; 2016 Jun 27; 37(6):7555-64. PubMed ID: 26684804
    [Abstract] [Full Text] [Related]

  • 7. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D.
    Mol Cancer Ther; 2020 Aug 27; 19(8):1623-1635. PubMed ID: 32430484
    [Abstract] [Full Text] [Related]

  • 8. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
    Kerr M, Scott HE, Groselj B, Stratford MR, Karaszi K, Sharma NL, Kiltie AE.
    Clin Cancer Res; 2014 Nov 01; 20(21):5435-45. PubMed ID: 25224279
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ.
    Mol Cancer Ther; 2002 Apr 01; 1(6):371-6. PubMed ID: 12477049
    [Abstract] [Full Text] [Related]

  • 10. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS, van der Wilt CL, Loves WJ, Padron JM, Eriksson S, Talianidis I, Peters GJ.
    Biochem Pharmacol; 2004 Aug 15; 68(4):601-9. PubMed ID: 15276067
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA.
    Clin Cancer Res; 2006 Apr 15; 12(8):2492-7. PubMed ID: 16638857
    [Abstract] [Full Text] [Related]

  • 12. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M.
    Clin Cancer Res; 2004 May 01; 10(9):2936-43. PubMed ID: 15131028
    [Abstract] [Full Text] [Related]

  • 13. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
    Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G.
    Mol Ther; 2006 Dec 01; 14(6):758-67. PubMed ID: 17000136
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J, Qian C.
    Med Oncol; 2010 Sep 01; 27(3):1017-22. PubMed ID: 19816816
    [Abstract] [Full Text] [Related]

  • 15. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
    Wei SH, Dong K, Lin F, Wang X, Li B, Shen JJ, Zhang Q, Wang R, Zhang HZ.
    Cancer Chemother Pharmacol; 2008 Nov 01; 62(6):1055-64. PubMed ID: 18297287
    [Abstract] [Full Text] [Related]

  • 16. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.
    Cancer Biol Ther; 2014 Jun 01; 15(6):688-98. PubMed ID: 24618665
    [Abstract] [Full Text] [Related]

  • 17. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
    Br J Cancer; 2007 Feb 12; 96(3):457-63. PubMed ID: 17224927
    [Abstract] [Full Text] [Related]

  • 18. HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
    Cao F, Li J, Sun H, Liu S, Cui Y, Li F.
    Oncol Rep; 2015 Apr 12; 33(4):1883-9. PubMed ID: 25672829
    [Abstract] [Full Text] [Related]

  • 19. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
    Guo Q, Chen Y, Wu Y.
    Tumori; 2009 Apr 12; 95(6):796-803. PubMed ID: 20210246
    [Abstract] [Full Text] [Related]

  • 20. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J, Yang J, Ramachandran V, Arumugam T, Deng D, Li Z, Xu L, Logsdon CD.
    PLoS One; 2015 Apr 12; 10(12):e0144969. PubMed ID: 26709920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.